{"id":"W4403789396","doi":"10.1016/j.ygyno.2024.10.013","title":"Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha–expressing recurrent ovarian cancer: An integrated safety summary","year":2024,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"ImmunoGen","keywords":"Medicine; Tolerability; Ovarian cancer; Oncology; Folate receptor; Internal medicine; Gynecology; Cancer; Adverse effect; Cancer cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002430051,0.0003456046,0.001228805,0.0002372176,0.0001739125,0.0000412026,0.0002446387,0.0005803849,0.00177025],"category_scores_gemma":[0.0007248915,0.0002746588,0.0001718911,0.0004896633,0.000513273,0.0001653293,0.0001077385,0.0007684699,0.000007136069],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001827066,"about_ca_system_score_gemma":0.002226562,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005615245,"about_ca_topic_score_gemma":0.001005911,"domain_scores_codex":[0.9964635,0.0006302142,0.001004572,0.0009310822,0.0002767704,0.0006939032],"domain_scores_gemma":[0.9969462,0.001614558,0.0001866883,0.0005069852,0.0004216821,0.0003239306],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.009015281,0.0007846024,0.003432797,0.0007631968,0.0002827296,0.00005358326,0.0009076644,0.00002335907,0.01857753,0.0005770151,0.005311165,0.9602711],"study_design_scores_gemma":[0.006799227,0.01399786,0.01493763,0.0006352931,0.0002152604,0.00005239037,0.0004045323,0.01006964,0.003383072,0.001416829,0.9476672,0.000421057],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8939148,0.03446342,0.01141186,0.03673067,0.006202848,0.008687099,0.002961568,0.0007755054,0.004852256],"genre_scores_gemma":[0.9188371,0.02406582,0.04935006,0.002027615,0.001090906,0.001129104,0.00116078,0.0002244921,0.002114145],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.95985,"threshold_uncertainty_score":0.9999706,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05559084458819756,"score_gpt":0.4069770437203846,"score_spread":0.351386199132187,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}